Meeting
2014 ASCO Annual Meeting
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.
Authors
Harriet M. Kluger
Yale University, New Haven, CT
Harriet M. Kluger , Susan Halabi , Nicole C Solomon , Lucia Jilaveanu , Christopher Zito , Joshua Sznol , Andrew B. Nixon , Brian I. Rini , Eric Jay Small , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4532)
DOI
10.1200/jco.2014.32.15_suppl.4532
Abstract #
4532
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).
First Author: Andrew B. Nixon
Poster
2012 ASCO Annual Meeting
Serum hepatocyte growth factor and interleukin-6 as prognostic markers for stage III non-small cell lung cancer.
First Author: Hideki Ujiie
First Author: Kimberly Stephanie Meza
Poster
2017 ASCO Annual Meeting
Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).
First Author: Daniel J. George